Sustained Or Differential Release Patents (Class 424/457)
  • Patent number: 10272033
    Abstract: Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and volatile organic solvents, yet the carbohydrate-glass particles are insoluble in organic solvents. A method for formulation of the polymeric compositions containing ambient-temperature stable biopharmaceuticals includes combining biopharmaceuticals encapsulated in carbohydrate-glass particles with polymer in organic solvent and evaporating the organic solvent to yield a water soluble polymeric composition containing ambient-temperature stable biopharmaceuticals.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: April 30, 2019
    Assignee: UNIVERSAL STABILIZATION TECHNOLOGIES, INC
    Inventor: Victor Bronshtein
  • Patent number: 10251857
    Abstract: A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes diethyl azelate at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: April 9, 2019
    Assignee: New Frontier Labs, LLC
    Inventors: Robert T. Streeper, Elzbieta Izbicka
  • Patent number: 10105552
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 23, 2018
    Assignee: Pharmacyclics LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • Patent number: 10039752
    Abstract: The present invention relates to methods of using methazolamide to treat pancreatic cancer. Pancreatic cancer can be treated by administering to a patient in need thereof an effective amount of methazolamide, optionally in combination with one or more additional cancer therapies.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: August 7, 2018
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 10022367
    Abstract: The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: July 17, 2018
    Assignee: Indivior UK Limited
    Inventors: Mingxing Zhou, Richard L. Norton
  • Patent number: 9980946
    Abstract: A once-a-day controlled release oral dosage form of methazolamide is provided. The dosage form comprises a therapeutically effective amount of methazolamide and a high molecular weight binder. The dosage is configured for once-daily administration to a subject in need thereof, and releases methazolamide over a period of about twenty-four hours.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: May 29, 2018
    Assignee: EFFCON LABORATORIES, INC.
    Inventor: Nabil Rizk
  • Patent number: 9943503
    Abstract: The present invention relates to a pharmaceutical composition comprising an effective amount of vitamin C, zinc, vitamin A, vitamin D3, garlic, and Echinacea to treat bacterial and/or viral infections, and a method for treating bacterial and/or viral infections by orally administering the composition to a patient effective to reduce the symptoms of bacterial and/or viral infections such as colds and influenza.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: April 17, 2018
    Inventor: Edward Wick
  • Patent number: 9937164
    Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: April 10, 2018
    Assignee: Camurus AB
    Inventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
  • Patent number: 9889093
    Abstract: The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: February 13, 2018
    Assignee: Tasly Pharmaceutical Group Co., Ltd.
    Inventors: Henry Sun, Xiaohui Ma, Zhixin Guo, Sen Lin, Genbei Wang, Lulu Yan, Lihua Zhang, Shuiping Zhou, Shunnan Zhang
  • Patent number: 9861700
    Abstract: The present invention concerns a natural biocomposite powder prepared from the biomass of yeast Pichia pastoris, comprising chitin-glucan complex (CGC) and mannose-containing polysaccharides. In a second aspect, the invention concerns the method of preparation of the natural biocomposite powder. The invention also concerns the method to obtain Pichia pastoris biomass with increased CGC content, as well as increased chitin to glucan content in the CGC. Finally, the invention concerns the use of the natural biocomposite powder, prepared from the cell wall of yeast Pichia pastoris by the method according to the invention, as excipient in the pharmaceutical, cosmetics or food industries.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 9, 2018
    Assignee: Pharma73, S.A.
    Inventors: Maria Filomena Andrade De Freitas, Christophe François Aimé Roca, Fernando Miguel Da Silva Cruz, Maria D'Ascensão Carvalho Fernandes De Miranda Reis, Inês Da Silva Farinha, Bárbara Ferreira Chagas, Rui Manuel Freitas Oliveira
  • Patent number: 9814671
    Abstract: An orifice-free drug delivery device is provided. In an embodiment, the device includes a body having at least one water-permeable wall bounding a reservoir defined within the body. A drug formulation is disposed within the reservoir. The body has an elastic portion and at least one restraining plug closing off an opening of the body. The opening is in fluid communication with the reservoir, and the restraining plug contacts the elastic portion of the body and controls release of the drug from the device by the transient formation of one or more microchannels between the elastic portion of the body and the at least one restraining plug. The elastic portion may define an opening having an inner diameter, which is exceeded by the outer diameter of the restraining plug by at least 3%.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 14, 2017
    Assignee: TARIS Biomedical LLC
    Inventor: Heejin Lee
  • Patent number: 9782353
    Abstract: The present invention provides a film coated tablet comprising a first film coating layer comprising hydroxypropyl methylcellulose and a second film coating layer comprising polyvinyl alcohol, on a tablet containing choline alfoscerate as an active ingredient and magnesium aluminometasilicate as an additive; and a process for preparing the same.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: October 10, 2017
    Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Sang-Han Park, Hee-Chul Chang
  • Patent number: 9763884
    Abstract: The invention relates to a time controlled, immediate release drug delivery system for oral administration of a first active ingredient to a subject in need thereof. The invention additionally relates to a dual drug delivery device, comprising the time controlled, immediate release drug delivery system according to the invention, further comprising a second coating comprising a second active ingredient.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: September 19, 2017
    Assignee: EB IP HYBRITABS B.V.
    Inventors: Johannes Martinus Maria Bloemers, Anko Cornelus Eissens, Henderik Willem Frijlink, Leonardus Gerardus Jozef De Leede
  • Patent number: 9766257
    Abstract: The present disclosure describes a method of detecting a drug marker in urine a urine sample using a toilet. The drug markers are fluorophores each of which emits a unique fluorescence spectra. Accordingly, the method does not detect the drug but rather, the drug marker. The drug marker may include quantum dots which may be functionalized by connecting the quantum dot to a biomolecule. The biomolecule may be cleavable by a peptidase, a protease, or a nuclease to release the drug. Alternatively, the composition may include a liposome carrier. A user who has consumed the drug composition urinates into the toilet and a urine sample is captured. The toilet includes a mechanism for fluid handling which diverts urine into a fluorescence spectrometer. The fluorescence spectrometer screens the urine for drug markers based on their unique fluorescent spectra.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: September 19, 2017
    Inventors: David R. Hall, Conrad Rosenbrock, Ben Swenson, Daniel Hendricks, Joe Fox, Terrece Pearman
  • Patent number: 9758676
    Abstract: A non-aqueous liquid concentrate includes starch, an acrylic acid homopolymer salt, vegetable oil, and clay. The non-aqueous liquid concentrate forms an aqueous dispersion when added to water and is capable of clinging to a surface.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: September 12, 2017
    Assignee: EarthClean Corporation
    Inventors: Liana Victoria Palaikis, Robert Glade Bowman, Olaf Christian Moberg, Anthony Robert Nelson, William Arthur Hendrickson, Christopher John Rueb, Neng Xiong, Kerstin Kristina Iverson
  • Patent number: 9750703
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: September 5, 2017
    Assignee: Purdue Pharma L.P.
    Inventor: Haiyong Hugh Huang
  • Patent number: 9737530
    Abstract: The present disclosure relates to cured pharmaceutical compositions designed to reduce the potential for improper administration of drugs that are subject to abuse, the process of curing such composition in order to improve the dissolution stability, method of using the same for treatment of pain.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: August 22, 2017
    Assignee: COLLEGIUM PHARMACEUTICAL, INC.
    Inventors: Said Saim, Alison B. Fleming, Ravi K. Varanasi
  • Patent number: 9668977
    Abstract: The invention relates to a coating composition suitable for the coating of pharmaceutical or nutraceutical dosage form, comprising a core comprising one or more pharmaceutical or nutraceutical active ingredients, wherein the coating composition is comprising at least 20% by weight of an enteric core/shell polymer composition derived from an emulsion polymerization process, wherein the core of the core/shell polymer composition is formed by a water-insoluble, cross-linked polymer or copolymer and the shell of the core/shell polymer composition is formed by an anionic polymer or copolymer.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: June 6, 2017
    Assignee: Evonik Röhm GmbH
    Inventors: Jan Hendrik Schattka, Christian Meier, Florian Hermes
  • Patent number: 9579285
    Abstract: The invention relates to a method for the preparation of a powdery pharmaceutical composition comprising a pharmaceutical excipient and a pharmaceutical component, the method comprising the step of extruding a mixture of the pharmaceutical excipient and the pharmaceutical component in an extruder at a temperature profile allowing a liquid melt of the mixture to congeal in the extruder and to exit the extruder in form of a powder.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: February 28, 2017
    Assignee: GRUENENTHAL GMBH
    Inventor: Marcel Haupts
  • Patent number: 9579288
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: February 28, 2017
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • Patent number: 9555005
    Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: January 31, 2017
    Assignee: Upsher-Smith Laboratories, Inc.
    Inventors: Sarah Michelle Betterman, Jaidev Srinivas Tantry, Laura Marie Patrick
  • Patent number: 9504656
    Abstract: Described herein are pharmaceutical compositions for the delivery of poorly soluble active pharmaceutical ingredients. In particular, a substantially clear fexofenadine HCl solution in a soft gelatin capsule is described.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: November 29, 2016
    Assignee: Banner Life Sciences, LLC
    Inventors: George Vamvakas, Aqeel A. Fatmi
  • Patent number: 9486454
    Abstract: Embodiments of a hydrazaline hydrochloride composition for treatment of hypertension in humans each provide sustained release of hydralazine hydrochloride administered in the form of pellets, granules and tablets. Methods of preparation are disclosed.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: November 8, 2016
    Inventor: Navaneeta K. Gorrepati
  • Patent number: 9486451
    Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: November 8, 2016
    Assignee: Recro Gainesville LLC
    Inventors: Gurvinder S. Rekhi, Richard Sidwell
  • Patent number: 9480667
    Abstract: An NSAID formulation for encapsulation into a soft gel capsule with increased stability, concentration and bioavailability of the NSAID. The preferred NSAIDS are naproxen, ibprofen, indomethacin and diclofenac, which are provided in both an acidic and basic form in the fill formulation. The pH values of fill formulations may be adjusted without additional process steps. A process for increasing the achievable concentration of an NASAID pharmaceutical ingredient in a fill composition for dosage units is also provided. The highly concentrated NASAID formulation permits a reduction in the fill volume or dosage unit size or an increase in concentration of the NSAID in each dosage it.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: November 1, 2016
    Assignee: ACCUCAPS INDUSTRIES LIMITED
    Inventors: John Lopez, Peter Draper, Sankalp Vashishtha, Nancy Klassen, Christina Armstrong
  • Patent number: 9403032
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: August 2, 2016
    Assignee: Pharmacyclics LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • Patent number: 9387166
    Abstract: The present invention relates to a controlled-release oral dosage form for administration of oxycodone once a day and a method of preparing a controlled-release oral dosage form for administration of oxycodone once a day.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: July 12, 2016
    Assignee: DEVELCO PHARMA SCHWEIZ AG
    Inventors: Hélène Rey, Marc Fischer, Mathias Scheer, Dirk Kramer
  • Patent number: 9371523
    Abstract: The present invention provides a cell migration regulator capable of promoting or inhibiting cell migration, a method for regulating cell migration, and a pharmaceutical composition comprising such a regulator, etc. The cell migration regulator of the present invention comprises a peptide, a derivative thereof, or a salt of the peptide or the derivative, wherein the peptide comprises the full-length blood coagulation factor IX, a segment derived from the full-length blood coagulation factor IX by removal of the trypsin domain, the light chain of blood coagulation factor IX, or the EGF1 domain of blood coagulation factor IX, or the EGF3 domain of the endothelial cell locus-1 protein.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: June 21, 2016
    Assignee: NIHON UNIVERSITY
    Inventors: Chiaki Hidai, Hisataka Kitano, Atsushi Mamiya
  • Patent number: 9327264
    Abstract: The invention provides a method for producing a mixture of amorphous compounds, the method comprising supplying a solution containing the compounds; and allowing at least a portion of the solvent of the solution to evaporate while preventing the solute of the solution from contacting a nucleation point. Also provided is a method for transforming solids to amorphous material, the method comprising heating the solids in an environment to form a melt, wherein the environment contains no nucleation points; and cooling the melt in the environment.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: May 3, 2016
    Assignee: UCHICAGO ARGONNE, LLC
    Inventors: Chris J. Benmore, Johann R. Weber
  • Patent number: 9198453
    Abstract: The present invention is directed to methods for reducing blood lactate concentration during exercise, physical activity or athletic performance.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: December 1, 2015
    Assignee: STOKELY-VAN CAMP, INC.
    Inventors: Jeffrey J. Zachwieja, Mark Arthur Pirner, JohnEric Smith
  • Patent number: 9202008
    Abstract: The various embodiments of the method of the present invention include a method to improving or expanding the capacity of a sleep analysis unit or laboratory, a method sleep analysis testing a patient admitted for diagnosis or treatment of another primary medical condition while being treated or diagnosed for that condition, a method of sleep analysis testing a patient that cannot be easily moved or treated in a sleep analysis unit or laboratory and other like methods.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: December 1, 2015
    Assignee: Cleveland Medical Devices Inc.
    Inventors: Craig A. Frederick, Hani Kayyali, Robert N. Schmidt, Brian M. Kolkowski
  • Patent number: 9161919
    Abstract: A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: October 20, 2015
    Assignee: Adare Pharmaceuticals, Inc.
    Inventor: Gopi M. Venkatesh
  • Patent number: 9101636
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: August 11, 2015
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 9034377
    Abstract: The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady state Cave and the steady state AUC of the first and second dosage forms are dose proportional and the single dose Cmax of the second dosage form is less than the minimum level for dose proportionality with respect to the first dosage form. The present invention also relates to methods of administering such dosage forms to a patient, as well as to kits comprising such dosage forms and instructions for administration of the dosage forms to a patient. The inventors believe that the dosage forms and methods of the present invention will lead to improved safety and patient acceptance.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 19, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Curtis Wright, Robert Colucci, Ahmed El-Tahtawy
  • Patent number: 9023388
    Abstract: A high-efficacy, long-acting formulation of silibinin, comprising silibinin solid dispersion, silibinin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silibinin solid dispersion:silibinin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silibinin-loaded silica nanoparticles is 51.29˜51.77%; the said silibinin solid dispersion contains povidone K30, soybean lecithin, acrylic resin IV, wherein the mass ratio between silibinin and other medical accessories is silibinin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silibinin disclosed in this invention is 14.8 times longer while the mean residence time (MRT) of which is 4.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: May 5, 2015
    Assignee: Jiangsu University
    Inventors: Ximing Xu, Jiangnan Yu, Xia Cao, Yuan Zhu
  • Publication number: 20150104505
    Abstract: Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 16, 2015
    Inventors: Manish S. SHAH, Ray J. DiFalco
  • Patent number: 9005943
    Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: April 14, 2015
    Assignee: The Invention Science Fund I, LLC
    Inventors: Ed Harlow, Roderick A. Hyde, Edward K. Y. Jung, Robert Langer, Eric C. Leuthardt, Lowell L. Wood, Jr.
  • Publication number: 20150071997
    Abstract: Methods of encapsulating cargo in a microgel droplet, microgel droplets prepared according the provided methods, and methods of use thereof are disclosed. The methods of preparing cargo-encapsulated microgels generally include flowing through a flow-focusing nozzle of a microfluidic device a macromer phase, an oil phase, and a crosslinker phase to form microgel droplets by oil-water emulsion. The phases are pumped, injected, or flowed through the microfluidic device such that as the macromer phase approaches the flow focusing nozzle, the co-flowing oil phase shields the macromer from contact with the crosslinker phase until flow instability occurs and macromer phase droplets form. After flow instability occurs, the crosslinker diffuses from the crosslinker phase into the droplets in an effective amount to covalently crosslink the macromer into a microgel network encapsulating the cargo in the crosslinked macromer.
    Type: Application
    Filed: September 9, 2014
    Publication date: March 12, 2015
    Inventors: Andres Garcia, Devon Headen, Edward A. Phelps, Guillaume A. Aubry, Hang Lu, Cristina Gonzalez Garcia
  • Publication number: 20150071998
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 12, 2015
    Inventors: Manish S. Shah, Ray J. DiFalco
  • Patent number: 8975273
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: March 10, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
  • Patent number: 8975271
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 10, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
  • Patent number: 8969369
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 3, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Frank S. Caruso, Huai-Hung Kao
  • Patent number: 8962017
    Abstract: A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin solid dispersion contains povidone K30, soybean lecithin and acrylic resin IV, and the mass ratio between silymarin and other medical accessories in silymarin solid dispersion is silymarin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silymarin disclosed in this invention is 2.3 times longer while the mean residence time (MRT) of which is 9.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: February 24, 2015
    Assignee: Jiangsu University
    Inventors: Ximing Xu, Jiangnan Yu, Shanshan Tong, Yuan Zhu, Xia Cao
  • Publication number: 20150050334
    Abstract: The present invention relates to new acid resistant hard pharmaceutical capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration of pharmaceuticals, veterinary products, food and dietary supplements to humans or animals. The capsules of the invention are obtained by aqueous compositions comprising a water soluble film forming polymer and gellan gum in a mutual weight ratio of 4 to 15 weight parts of gellan gum for 100 weight parts of film forming polymer.
    Type: Application
    Filed: August 27, 2014
    Publication date: February 19, 2015
    Inventors: Dominique Nicolas Cade, Xiongwei David He
  • Publication number: 20150050335
    Abstract: The present disclosure relates to methods for making extended-release formulations of water-soluble active pharmaceutical ingredients such as metformin HCl. In one aspect, the disclosure provides a method that includes adding an aqueous solution of an active pharmaceutical ingredient to an agitated mixture of one or more release-modifying polymers and optionally one or more binders in one or more organic solvents, the one or more organic solvents together being an antisolvent for the active pharmaceutical ingredient, water being sufficiently soluble in the one or more organic solvents such that the water added as part of the aqueous solution dissolves in the mixture, the addition thereby precipitating the active pharmaceutical ingredient; separating the active pharmaceutical ingredient and the one or more release-modifying polymers and, if present, the one or more binders from the one or more organic solvents to yield co-processed particles; and drying the co-processed particles.
    Type: Application
    Filed: February 28, 2013
    Publication date: February 19, 2015
    Inventors: Deniz Erdemir, Shih-Ying Chang, Divyakant Desai, San Kiang
  • Patent number: 8956647
    Abstract: An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: February 17, 2015
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Norbert Otterbeck, Peter Gruber
  • Publication number: 20150044283
    Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
  • Publication number: 20150037405
    Abstract: The present invention relates to pharmaceutical compositions of levodopa and carbidopa. In particular, the invention relates to modified release pharmaceutical compositions of levodopa and carbidopa with at least one organic acidic excipient. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of Parkinson's disease.
    Type: Application
    Filed: August 4, 2014
    Publication date: February 5, 2015
    Inventors: Sushrut Krishnaji Kulkarni, Pavak Rajnikant Mehta, Sameer Sagar Kochar, Krishnakumar Vinubhai Patel
  • Patent number: 8945615
    Abstract: Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, an extended release polymer, and an acid. The budesonide may be embedded in the extended release polymer to facilitate extended release of the budesonide upon administration.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: February 3, 2015
    Assignee: Mylan Pharmaceuticals Inc.
    Inventors: Mummini Aruna Murty, Boyong Li
  • Patent number: 8945616
    Abstract: Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, and an extended release polymer. The budesonide may be embedded in the extended release polymer to facilitate extended release of the budesonide upon administration.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: February 3, 2015
    Assignee: Mylan Pharmaceuticals Inc.
    Inventors: Mummini Aruna Murty, Boyong Li